Neoplasm and Fluorouracil


Neoplasm Symptoms and Causes

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation.

NIH: National Cancer Institute

Check out the latest treatments for neoplasm

neoplasm treatment research studies

Fluorouracil clinical trials, surveys and public health registries

Find Drug Side Effect reports

Fluorouracil Side Effects

Diarrhoea (463)
Nausea (335)
Dehydration (273)
Vomiting (266)
Neutropenia (243)
Febrile Neutropenia (207)
Pyrexia (187)
Mucosal Inflammation (179)
Asthenia (158)
Abdominal Pain (152)
Stomatitis (143)
Fatigue (134)
Dyspnoea (131)
Interstitial Lung Disease (117)
Decreased Appetite (116)
Pulmonary Embolism (111)
Chest Pain (110)
Anaemia (106)
Thrombocytopenia (106)
Hypotension (106)
Neutrophil Count Decreased (99)
Hypokalaemia (95)
Leukopenia (83)
Sepsis (78)
White Blood Cell Count Decreased (78)
Renal Failure Acute (75)
Pneumonia (75)
Malaise (74)
Haemoglobin Decreased (72)
Neuropathy Peripheral (69)
Pain (69)
Renal Failure (64)
Disease Progression (64)
Respiratory Failure (62)
Cardiotoxicity (62)
Dysphagia (61)
Confusional State (57)
Platelet Count Decreased (57)
Pancytopenia (55)
Fall (55)
Deep Vein Thrombosis (54)
Myocardial Infarction (53)
Arteriospasm Coronary (51)
Hyponatraemia (51)
Weight Decreased (51)
Tachycardia (48)
Chills (46)
Dizziness (46)
Septic Shock (46)
Hyperammonaemia (46)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Neoplasm Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Condition: Metastatic Colorectal Cancer
Interventions: Drug: CY;   Biological: GVAX;   Drug: SGI-110
Outcome Measures: Difference in CD45RO+ tumor infiltrating lymphocytes (TILs) measured by immunohistochemistry in pre and post-treatment tumor biopsies from patients with metastatic colorectal cancer;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   Overall Survival (OS);   Time To Progression (TTP);   Progression Free Survival (PFS)
2 Unknown  Early Detection of Cancers in Low Resource Countries
Conditions: Breast Neoplasms;   Uterine Cervical Neoplasms;   Ovarian Neoplasms;   Endometrial Neoplasms
Interventions: Procedure: Breast Cancer Screening and Diagnosis;   Procedure: Cervical Cancer Screening and Diagnosis;   Procedure: Ovarian Cancer Screening and Diagnosis;   Procedure: Endometrial Cancer Screening and Diagnosis
Outcome Measures: The Effectiveness of an Innovative, Low-Cost Screening and Diagnostic Methodology;   Effectiveness of CBE and Ultrasonography for Breast Cancer Detection
3 Recruiting Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Conditions: Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Breast Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Other: cytology specimen collection procedure;   Other: laboratory biomarker analysis
Outcome Measures: Feasibility of NGS on metastatic solid tumor tissue, in terms of number of patients screened, FMI test attempted, FMI test successful, and FMI tests results released to physicians;   Feasibility of NGS result-based non-FDA-approved treatment plan, measured by reasons for ability or inability to receive an anti-cancer agent;   Availability of recommended experimental regimens via clinical trials;   Proportion of patients who have one recommended therapy;   Proportion of patients who have multiple options recommended;   Presence of any oncogene or tumor suppressor gene mutations or amplifications identified by NGS on tumor tissue in each cohort
4 Recruiting Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
Outcome Measures: Tabulation of toxicity type and grade;   To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.;   To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.
5 Recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Conditions: Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Extrapulmonary Small Cell Cancer;   Pulmonary Neuroendocrine Tumors;   Thymic Epithelial Tumors
Outcome Measures: Allow sample acquisition for use in the study of thoracic malignancies except mesothelioma.;   Follow the natural history of patients with thoracic malignancies.;   Conduct genomic, proteomic and immunological analyses on blood, tumor, body fluid and normal tissue in support of NIH translational trials to develop new therapeutic agents and novel treatment approaches as well as new prognostic and diagnostic ...
6 Recruiting Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Conditions: Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancy
Interventions: Biological: Epigenetically Modified Autologous Tumor;   Drug: Cyclophosphamide;   Drug: Celecoxib
Outcome Measures: To assess the safety of an epigenetically modified autologous tumor cell vaccine administered with ISCOMATRIX adjuvant in combination with metronomic oral cyclophosphamide and celecoxib in patients undergoing thoracic metastasectomy.;   To ascertain if autologous epigenetically modified tumor cell vaccines induce immunity to CTAs in patients following thoracic metastasectomy.;   To assess feasibility, reliability, and reproducibility of establishing Tumor lines from patients with thoracic malignancies;   To examine effect of oral metronomic CP + celecoxib in number of T regs.
7 Recruiting Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy
Conditions: Solid Tumors;   Hematologic Cancers
Intervention: Other: molecular profiling of tumors
Outcome Measures: frequency of "actionable" oncogenic mutations;   To determine the impact of molecular profiling results performed in the CLIA-setting on the treatment of patients.;   interrogate the mechanisms;   To explore the genetic mechanisms of tumorigenesis
8 Recruiting Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
Conditions: Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancies
Intervention: Biological: Allogenic Tumor Cell Vaccine (K562)
Outcome Measures: To assess the safety of K562-GM allogeneic tumor cell vaccines in combination with oral metronomic cyclophosphamide and celecoxib in patients undergoing thoracic metastasectomy.;   Ascertain if K562-GM cell vaccines induce immunity to CTAs in patients following thoracic metastasectomy.;   To examine if oral metronomic CP and celecoxib therapy reduces the number, activity and percentage of T regs cells in this patient population.
9 Recruiting Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Conditions: Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Sarcoma;   Uterine Leiomyomata;   Vaginal Cancer;   Vulvar Cancer
Interventions: Other: laboratory biomarker analysis;   Other: screening questionnaire administration;   Procedure: study of high risk factors
Outcome Measures: Identification and development of highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies;   Identification of new prevention approaches and therapies;   Identification of measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer
10 Recruiting Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Conditions: Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dovitinib lactate;   Drug: gemcitabine hydrochloride;   Drug: capecitabine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: pharmacological study
Outcome Measures: Maximum tolerated dose (MTD) is defined as the highest dose level at which less than 33% of patients experience study treatment-related dose limiting toxicities (DLT);   Overall safety profile characterized by type, frequency, severity (according to National Cancer Institute [NCI] CTCAE version 4.0), timing, seriousness and relationship to study treatment;   Plasma pharmacokinetic parameters of dovitinib lactate, gemcitabine hydrochloride, capecitabine and their metabolites;   Solid tumor/dose-finding cohort: response rate, progression free survival;   Pancreas cancer cohort: survival, response rate and progression free survival;   Pharmacodynamic effects of dovitinib lactate and Gem-Cap combination on vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptors (FGFR) dynamics in serum and tumor specimens
11 Recruiting Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions: Drug: AZD;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
Outcome Measures: To determine the feasibility of the use of tumor s molecular profiling and targeted therapies in the treatment of NSCLC, SCLC, and Thymic Malignancies;   To estimated the response rate of molecular-profile directed treatments in NSCLC, SCLC, and Thymic Malignancies;   To determine Progression Free Survival, duration of response, and overall survival;   To evaluate changes in the tumor s molecular profile on serial biopsies when patients progress after an initial response to treatment.;   To identify molecular profiles in patients with NSCLC, SCLC, and Thymic Malignancies
12 Recruiting Genomic Testing for Primary Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: Tumor Biopsy;   Other: Breast Cancer Registry
Outcome Measure: Feasibility Analysis of Genomic Predictor from Localized Invasive Breast Cancer Tumor Registry
13 Recruiting A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Conditions: Breast Cancer;   Lung Cancer;   Renal Cancer;   Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Outcome Measures: Determine if the FPAC uptake in tumors is different than the uptake in normal background tissues; Determine safety of FPAC administration;   Compare FPAC uptake with FDG uptake in solid tumors; make preliminary comparisons of FPAC uptake with treatment response and drug transporter expression when available
14 Recruiting Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
Conditions: Malignant Solid Tumour;   Breast Cancer Nos Metastatic Recurrent;   Neuropathy
Intervention: Drug: Eribulin in Combination w/ Cyclophosphamide
Outcome Measures: Phase Ib: 1. Maximum tolerated dose (MTD) of eribulin in combination with cyclophosphamide in patients with any solid tumor;   Phase II 1. Clinical benefit (complete response, partial response, and stable disease) of the combination of eribulin and cyclophosphamide in patients with advanced breast cancer;   Phase Ib: 1. Safety of treatment;   Phase Ib: 2. Dose Limiting Toxicity (DLT);   Phase Ib: 3. Pharmacokinetics (PK) and potential for drug-drug interaction;   Phase Ib: 4. Quality of life;   Phase Ib: 5. Pharmacodynamic, pharmacogenomic and response prediction biomarkers;   Phase II 1. Efficacy of drug combination in patients with advanced breast cancer including response rate, duration of response and time to progression;   Phase II 2. Safety of drug combination in expanded cohort - metastatic breast cancer;   Phase II 3. Quality of life endpoints;   Phase II 4. Pharmacodynamic, pharmacogenomic and response prediction biomarkers
15 Recruiting Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention: Procedure: Tumor Debulking Surgery (surgery in recurrent ovarian disease)
Outcome Measures: Overall survival in patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score;   Quality of Life;   Progression free survival
16 Unknown  Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Esophageal Cancer;   Head and Neck Cancer;   Lung Cancer
Interventions: Other: 18F-fluoromisonidazole;   Other: fluorescence angiography;   Other: laboratory biomarker analysis;   Procedure: infrared thermography;   Procedure: magnetic resonance imaging;   Procedure: therapeutic conventional surgery;   Radiation: [18F]-ML-10;   Radiation: fludeoxyglucose F 18;   Radiation: rubidium Rb-82
Outcome Measures: Clinical, radiological, and pathological correlation;   Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates)
17 Recruiting A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Conditions: CD27 Expressing B-cell Malignancies, (for Example;   Chronic Lymphocytic Leukemia, Burkett's Lymphoma,;   Mantle Cell Lymphoma, Primary Lymphoma of the Central Nervous System,;   Marginal Zone B Cell Lymphoma);;   Any T-cell Malignancy;;   Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma,;   Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer;   Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)
Intervention: Drug: CDX-1127
Outcome Measures: Characterize the adverse events associated with CDX-1127 administration;   Levels of anti-CD27 antibodies in circulating blood.;   Levels of CDX-1127 in circulating blood.;   Activity Evaluations;   Immune system effects (eg: lymphoid cell populations and serum cytokine levels)
18 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combinaton With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
Outcome Measures: Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects (Phase 2);   Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects (Phase 3);   Investigator-determined Overall Response Rate (ORR) for triple negative metastatic breast cancer subjects (Phase 2);   Percentage of triple negative metastatic breast cancer subjects who initiated Cycle 6 (Phase 2);   Investigator determined Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects (Phase 2);   Safety for triple negative metastatic breast cancer (TNMBC) subjects (Phase 2);   Independent blinded radiologists-determined Overall Response Rate (ORR) for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Compare disease control rate for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Duration of Response for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Safety of each treatment regimen for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Investigator assessed Progression Free Survival (PFS)for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3)
19 Recruiting Hypodontia and Ovarian Cancer
Conditions: Ovarian Cancer;   Hypodontia;   Breast Cancer;   Colon Cancer
Outcome Measures: Prevalence rates of hypodontia in women with ovarian cancer;   Genetic causes for hypodontia and ovarian cancer;   Prevalence rates of hypodontia in patients with a known risk for epithelial cancer
20 Recruiting Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Conditions: Breast Cancer;   Bladder Cancer;   Kidney Cancer;   Colon Cancer;   Prostate Cancer;   Lung Cancer
Intervention: Genetic: PCR/PCR/LDR Strategy
Outcome Measures: To collect anonymized germline DNA from patients with breast, bladder, kidney, lung, colon, testicular, prostate, lymphoid, or head and neck cancers, as well as patients with multiple primary cancers, from select New York City ethnic groups.;   To analyze DNA samples from matched non-cancer individuals of the same ethnic groups available as part of the AMDeC-sponsored New York Cancer Study.